Holen Sie sich die Stockscreener-App
17.43
2.30%
-0.41
Handel nachbörslich:
17.34
-0.09
-0.52%
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo
Intellia CFO Edward Dulac III sells $84,186 in stock - Investing.com
Intellia CFO Edward Dulac III sells $84,186 in stock By Investing.com - Investing.com Australia
Form 4 Intellia Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada
Intellia Therapeutics (NTLA) VP sells shares to cover RSU tax - Stock Titan
Intellia (NTLA) CFO’s 4,677-share sale executed under 10b5-1 plan - Stock Titan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia lures 13 new employees with 53,250 stock awards - Stock Titan
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLAIntellia Therapeutics Inc Forecast, Target Price - Finviz
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] Intellia Therapeutics, Inc. SEC Filing - Stock Titan
NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% - The Globe and Mail
Investor Sentiment Divided in Healthcare Sector: Intellia Therap - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA): Can Innovation Justify the Buzz? - Kalkine Media
Price to book forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Price to earnings forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Price to book forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Price to sales forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Enterprise value to EBIT forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Price to sales forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Enterprise value to EBITDA forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Liquidity Mapping Around (NTLA) Price Events - Stock Traders Daily
Certain Stock Options of Intellia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2026. - marketscreener.com
Price to earnings forward of Intellia Therapeutics, Inc. – BOATS:NTLA - TradingView
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics - The National Law Review
Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Sh - The National Law Review
Intellia Therapeutics Inc (NTLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intellia Therapeutics Stock Short Interest Rises to 45.4% - Moomoo
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI
Intellia Therapeutics, Inc. Actuals & Estimates (NASDAQ:NTLA) - TradingView
NTLA Stock Price, Quote & Chart - ChartMill
Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors o - GuruFocus
Intellia Therapeutics, Inc. Actuals & Estimates (SWB:38I) - TradingView
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree - AOL.com
Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Jun 2026 $NTLA - MarketBeat
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why. - AOL.com
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):